MorphoSys AG's revenue for the
three
months ended in Dec. 2023 was €59.1 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €238.4 Mil.
MorphoSys AG's Revenue per Share for the
three
months ended in Dec. 2023 was €1.70.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €6.94.
Warning Sign:
MorphoSys AG revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of MorphoSys AG was -14.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -11.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 27.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 12.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, MorphoSys AG's highest 3-Year average Revenue per Share Growth Rate was 90.90% per year. The lowest was -31.80% per year. And the median was 6.50% per year.
MorphoSys AG Revenue Historical Data
The historical data trend for MorphoSys AG's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MorphoSys AG's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MorphoSys AG's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MorphoSys AG's Revenue distribution charts can be found below:
* The bar in red indicates where MorphoSys AG's Revenue falls into.
MorphoSys AG Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €238.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MorphoSys AG (WBO:MOR) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
MorphoSys AG Revenue Related Terms
Thank you for viewing the detailed overview of MorphoSys AG's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
WBO:MOR has been successfully added to your 